Table 5.
Number needed to treat or harm (95% confidence interval) compared with warfarin
| Outcome | 6 months | 12 months | 18 months | 24 months |
|---|---|---|---|---|
| With atrial fibrillation | ||||
| Numbers needed to treat: | ||||
| Major bleeding, apixaban | 182 (137 to 299) | 104 (78 to 170) | 76 (58 to 126) | 60 (45 to 99) |
| Intracranial bleed, dabigatran | 545 (407 to 1310) | 274 (204 to 658) | 196 (146 to 472) | 150 (111 to 360) |
| Intracranial bleed, apixaban | 501 (401 to 828) | 252 (201 to 416) | 180 (144 to 298) | 137 (110 to 227) |
| Numbers needed to harm: | ||||
| Mortality, rivaroxaban | 202 (131 to 410) | 118 (76 to 239) | 86 (56 to 175) | 70 (45 to 141) |
| Without atrial fibrillation | ||||
| Numbers needed to treat: | ||||
| Major bleeding, apixaban | 138 (102 to 257) | 85 (62 to 158) | 61 (45 to 114) | 49 (36 to 91) |
| Intracranial bleed, rivaroxaban | 592 (423 to 1528) | 323 (230 to 834) | 224 (160 to 579) | 185 (132 to 479) |
| All gastrointestinal bleed, apixaban | 293 (207 to 756) | 181 (128 to 467) | 126 (89 to 326) | 96 (68 to 248) |
| Upper gastrointestinal bleed, apixaban | 329 (232 to 891) | 200 (141 to 543) | 138 (97 to 375) | 108 (76 to 294) |
| Venous thromboembolism,* dabigatran | 34 (30 to 43) | 32 (28 to 40) | 30 (27 to 39) | 29 (26 to 37) |
| Venous thromboembolism,* apixaban | 44 (38 to 55) | 41 (35 to 51) | 40 (34 to 49) | 38 (33 to 47) |
| Numbers needed to harm: | ||||
| Venous thromboembolism,* rivaroxaban | 53 (38 to 80) | 49 (36 to 75) | 48 (34 to 72) | 46 (33 to 69) |
| Mortality, rivaroxaban | 61 (47 to 82) | 37 (29 to 49) | 27 (21 to 37) | 23 (18 to 30) |
The calculations are based on the hazard ratios derived from QResearch or combined analysis. Only statistically significant associations between the exposure and outcome are included.
*
Based on patients without venous thromboembolism before the start of anticoagulant